Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Employees: 51-200
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Roivant | roivant.co... |
Mentions in press and media 11
| Date | Title | Description |
| 01.11.2024 | HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update | HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expect... |
| 28.07.2024 | HanAll Biopharma: Navigating Challenges and Opportunities in Q2 2024 | HanAll Biopharma, a global player in the biopharmaceutical arena, recently unveiled its financial results for the second quarter of 2024. The numbers tell a story of resilience amid challenges. Total revenue reached 31.6 billion KRW, a slig... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 30.04.2024 | HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update | Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. Phase 3 VELOS-4 study of tanfaner... |
| 21.03.2024 | HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update | Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatme... |
| 12.03.2024 | Immunovant Awarded U.S. Patent for IMVT-1402 | - |
| 28.11.2023 | Today’s biotech news roundup, in under 800 words | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk lots about clinical trial inconsistencies: How Canada’s trial reporting is not up to snuff, and how c... |
| 04.10.2022 | Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock | - |
| 03.02.2021 | Immunovant plunges nearly 50% after pausing a trial for its eye drug after unexpected cholesterol finding | Shares of Immunovant plunged nearly 50% on Tuesday after the company announced a voluntary pause in its ongoing clinical trials for IMVT-1401. The drug, which is meant to cure thyroid eye disease, is the company's sole experimental candidat... |
Show more